Goodwin Procter and Davis Polk work on Global Blood’s $138 million IPO

Goodwin Procter represented South San Francisco-based Global Blood Therapeutics Inc. in its $138 million initial public offering, in which the company sold 6 million shares of common stock at $20 per share.